Company / Accounts Receivable
ADMA Biologics, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$158.4M
FY2025
5-year range
$15.5M / $158.4M
FY2021-FY2025
Trend
+216.9%
vs FY2024
Sector context
#37 of 115
Health Care
What the data says
Accounts Receivable changed +217% YoY in FY2025, a notable deviation from the 9-year average annual change of +122%.
Based on SEC 10-K filings.
$158M in FY2025 with a 5-year CAGR of +64.3%.
Improved from $27M to $158M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +117.0%
- 5-Year CAGR
- +64.3%
- 10-Year CAGR
- -
Sector benchmark
#37 of 115 in Health CareTop 32% of 115This company $158.4M Sector average $1.1B
▼
-85.8% below sector average
Key checks
Key Insights
- ADMA Biologics, Inc.'s accounts receivable has grown for 3 consecutive years.
- 5-year CAGR of +64.3%, indicating consistent growth.
- In FY2025, accounts receivable increased 216.9% year-over-year.
- Ranks #37 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $158.4M | +216.9% |
| FY2024 | $50.0M | +82.3% |
| FY2023 | $27.4M | +76.9% |
| FY2022 | $15.5M | -45.7% |
| FY2021 | $28.6M | +115.9% |
| FY2020 | $13.2M | +281.5% |
| FY2019 | $3.5M | +149.2% |
| FY2018 | $1.4M | -64.1% |
| FY2017 | $3.9M | +281.1% |
| FY2016 | $1.0M | +165.1% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026